D-Xylose suppresses adipogenesis and regulates lipid metabolism genes in high-fat diet-induced obese mice

Nutrition Research

Volumn 35, Issue 7, 2015, Pages 626-636

  Lim, Eunjin ^a   Lim, Ji Ye ^a   Shin, Jae Ho ^b   Seok, Pu Reum ^b   Jung, Sangwon ^c   Yoo, Sang Ho ^d   Kim, Yuri ^a  

^a Ewha Womans University   (South Korea)

^b Eulji University   (South Korea)

^c TS Corporation   (South Korea)

^d Sejong University   (South Korea)

Author keywords

Adipogenesis; D Xylose; High fat diet induced obesity; Lipid metabolism; Mice

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CHOLESTEROL; FAS ANTIGEN; FATTY ACID SYNTHASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; XYLOSE; XYLOSE 10; XYLOSE 5; LIPOPROTEIN; SWEETENING AGENT;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AP2 GENE; ARTICLE; ASSAY; C/EBPALPHA GENE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; FAS GENE; FATTY ACID OXIDATION; GAPDH GENE; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INTRAABDOMINAL FAT; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SREBP 1C GENE; SUBCUTANEOUS FAT; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ADIPOSE TISSUE; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DIETARY SUPPLEMENT; DRUG EFFECTS; DYSLIPIDEMIAS; GENETICS; LIPOLYSIS; LIVER; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MUS;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; CHOLESTEROL; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DOWN-REGULATION; DYSLIPIDEMIAS; LIPID METABOLISM; LIPOLYSIS; LIPOPROTEINS; LIVER; MALE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; SWEETENING AGENTS; XYLOSE;

EID: 84937517309     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2015.05.012     Document Type: Article

References (61)

1. Larsson B., Bjorntorp P., Tibblin G. The health consequences of moderate obesity. Int J Obes 1981, 5:97-116.
2. Bosello O., Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000, 1:47-56.
3. Bach A.C., Ingenbleek Y., Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy?. J Lipid Res 1996, 37:708-726.
4. Furuyashiki T., Nagayasu H., Aoki Y., Bessho H., Hashimoto T., Kanazawa K., et al. Tea catechin suppresses adipocyte differentiation accompanied by down-regulation of PPARgamma2 and C/EBPalpha in 3T3-L1 cells. Biosci Biotechnol Biochem 2004, 68:2353-2359.
5. Ghosh P., Bitsanis D., Ghebremeskel K., Crawford M.A., Poston L. Abnormal aortic fatty acid composition and small artery function in offspring of rats fed a high fat diet in pregnancy. J Physiol 2001, 533:815-822.
6. Rizvi F., Iftikhar M., George J.P. Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats. J Med Food 2003, 6:123-128.
7. Rosen E.D., Hsu C.H., Wang X., Sakai S., Freeman M.W., Gonzalez F.J., et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002, 16:22-26.
8. Feve B. Adipogenesis: cellular and molecular aspects. Best Pract Res Clin Endocrinol Metab 2005, 19:483-499.
9. Schmid B., Rippmann J.F., Tadayyon M., Hamilton B.S. Inhibition of fatty acid synthase prevents preadipocyte differentiation. Biochem Biophys Res Commun 2005, 328:1073-1082.
10. Kim J.B., Spiegelman B.M. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev 1996, 10:1096-1107.
11. Zhang Y.L., Hernandez-Ono A., Siri P., Weisberg S., Conlon D., Graham M.J., et al. Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem 2006, 281:37603-37615.
12. Evans R.M., Barish G.D., Wang Y.X. PPARs and the complex journey to obesity. Nat Med 2004, 10:355-361.
13. Tamura S., Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1139-1142.
14. Schattenberg J.M., Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol 2011, 22:479-488.
15. Niaz A., Ali Z., Nayyar S., Fatima N. Prevalence of NAFLD in healthy and young male individuals. ISRN Gastroenterol 2011, 2011:363546.
16. Koliaki C., Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol 2013, 379:35-42.
17. Kobayashi Y., Miyazawa M., Kamei A., Abe K., Kojima T. Ameliorative effects of mulberry (Morus alba L.) leaves on hyperlipidemia in rats fed a high-fat diet: induction of fatty acid oxidation, inhibition of lipogenesis, and suppression of oxidative stress. Biosci Biotechnol Biochem 2010, 74:2385-2395.
18. Rao M.S., Reddy J.K. PPARalpha in the pathogenesis of fatty liver disease. Hepatology 2004, 40:783-786.
19. Seo Y.S., Kim J.H., Jo N.Y., Choi K.M., Baik S.H., Park J.J., et al. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 2008, 23:102-109.
20. Horton T.J., Drougas H., Brachey A., Reed G.W., Peters J.C., Hill J.O. Fat and carbohydrate overfeeding in humans: different effects on energy storage. Am J Clin Nutr 1995, 62:19-29.
21. Brenner R.R., Rimoldi O.J., Lombardo Y.B., Gonzalez M.S., Bernasconi A.M., Chicco A., et al. Desaturase activities in rat model of insulin resistance induced by a sucrose-rich diet. Lipids 2003, 38:733-742.
22. Bae Y.J., Bak Y.K., Kim B., Kim M.S., Lee J.H., Sung M.K. Coconut-derived d-xylose affects postprandial glucose and insulin responses in healthy individuals. Nutr Res Pract 2011, 5:533-539.
23. Seri K., Sanai K., Matsuo N., Kawakubo K., Xue C., Inoue S. L-arabinose selectively inhibits intestinal sucrase in an uncompetitive manner and suppresses glycemic response after sucrose ingestion in animals. Metabolism 1996, 45:1368-1374.
24. Fordtran J.S., Soergel K.H., Ingelfinger F.J. Intestinal absorption of d-xylose in man. N Engl J Med 1962, 267:274-279.
25. Haeney M.R., Culank L.S., Montgomery R.D., Sammons H.G. Evaluation of xylose absorption as measured in blood and urine: a one-hour blood xylose screening test in malabsorption. Gastroenterology 1978, 75:393-400.
26. Wu T., Bound M.J., Zhao B.R., Standfield S.D., Bellon M., Jones K.L., et al. Effects of a d-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes. Diabetes Care 2013, 36:1913-1918.
27. Amo K., Arai H., Uebanso T., Fukaya M., Koganei M., Sasaki H., et al. Effects of xylitol on metabolic parameters and visceral fat accumulation. J Clin Biochem Nutr 2011, 49:1-7.
28. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
29. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
30. Millan J., Pinto X., Munoz A., Zuniga M., Rubies-Prat J., Pallardo L.F., et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009, 5:757-765.
31. Bermudez O.I., Gao X. Greater consumption of sweetened beverages and added sugars is associated with obesity among US young adults. Ann Nutr Metab 2010, 57:211-218.
32. Johnson R.K., Yon B.A. Weighing in on added sugars and health. J Am Diet Assoc 2010, 110:1296-1299.
33. Ruxton C.H., Gardner E.J., McNulty H.M. Is sugar consumption detrimental to health? A review of the evidence 1995-2006. Crit Rev Food Sci Nutr 2010, 50:1-19.
34. Malik V.S., Popkin B.M., Bray G.A., Despres J.P., Hu F.B. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation 2010, 121:1356-1364.
35. Craig R.M., Ehrenpreis E.D. d-xylose testing. J Clin Gastroenterol 1999, 29:143-150.
36. Brand-Miller J.C., Holt S.H., Pawlak D.B., McMillan J. Glycemic index and obesity. Am J Clin Nutr 2002, 76:281S-285S.
37. Medrikova D., Jilkova Z.M., Bardova K., Janovska P., Rossmeisl M., Kopecky J. Sex differences during the course of diet-induced obesity in mice: adipose tissue expandability and glycemic control. Int J Obes (Lond) 2012, 36:262-272.
38. Podrini C., Cambridge E.L., Lelliott C.J., Carragher D.M., Estabel J., Gerdin A.K., et al. High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice. Mamm Genome 2013, 24:240-251.
39. World Health Organization Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk 2007, WHO, Geneva, Switzerland.
40. Shimano H., Shimomura I., Hammer R.E., Herz J., Goldstein J.L., Brown M.S., et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 1997, 100:2115-2124.
41. Al-Hasani H., Joost H.G. Nutrition-/diet-induced changes in gene expression in white adipose tissue. Best Pract Res Clin Endocrinol Metab 2005, 19:589-603.
42. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 2009, 48:1-26.
43. Foretz M., Pacot C., Dugail I., Lemarchand P., Guichard C., Le Liepvre X., et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 1999, 19:3760-3768.
44. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
45. Loftus T.M., Jaworsky D.E., Frehywot G.L., Townsend C.A., Ronnett G.V., Lane M.D., et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288:2379-2381.
46. Makowski L., Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005, 16:543-548.
47. Shin S.S., Jung Y.S., Yoon K.H., Choi S., Hong Y., Park D., et al. The Korean traditional medicine gyeongshingangjeehwan inhibits adipocyte hypertrophy and visceral adipose tissue accumulation by activating PPARalpha actions in rat white adipose tissues. J Ethnopharmacol 2010, 127:47-54.
48. Umek R.M., Friedman A.D., McKnight S.L. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 1991, 251:288-292.
49. Christy R.J., Yang V.W., Ntambi J.M., Geiman D.E., Landschulz W.H., Friedman A.D., et al. Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 1989, 3:1323-1335.
50. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
51. Everett L., Galli A., Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000, 20:191-199.
52. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., et al. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 1994, 91:7355-7359.
53. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
54. Mannaerts G.P., Debeer L.J., Thomas J., De Schepper P.J. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J Biol Chem 1979, 254:4585-4595.
55. Stefanovic-Racic M., Perdomo G., Mantell B.S., Sipula I.J., Brown N.F., O'Doherty R.M. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008, 294:E969-E977.
56. Drynan L., Quant P.A., Zammit V.A. Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over beta-oxidation, ketogenesis and tricarboxylic acid cycle activity in hepatocytes isolated from rats in different metabolic states. Biochem J 1996, 317(Pt 3):791-795.
57. Moon S.L.K., Kyung M., Jung S., Park Y., Yang C. Study on the proper d-xylose concentration in sugar mixture to reduce glycemic index (GI) value in the human clinical model. Korean J Food Nutr 2012, 25:787-792.
58. Preuss H.G., Echard B., Bagchi D., Stohs S. Inhibition by natural dietary substances of gastrointestinal absorption of starch and sucrose in rats and pigs: 1. acute studies. Int J Med Sci 2007, 4:196-202.
59. Chung Y.M., Hyun Lee J., Youl Kim D., Hwang S.H., Hong Y.H., Kim S.B., et al. Dietary D-psicose reduced visceral fat mass in high-fat diet-induced obese rats. J Food Sci 2012, 77:H53-H58.
60. Joshi S.K., Liu X., Samagh S.P., Lovett D.H., Bodine S.C., Kim H.T., et al. mTOR regulates fatty infiltration through SREBP-1 and PPARγ after a combined massive rotator cuff tear and suprascapular nerve injury in rats. J Orthop Res 2013, 31:724-730.
61. Laplante M., Sabatini D.M. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009, 19:R1046-R1052.